Litcius/Paper detail

Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB

Nina Reuter, Barbara Kropff, Julia Karin Schneiderbanger, Mira Alt, Adalbert Krawczyk, Christian Sinzger, Thomas Winkler, William J. Britt, Michael Mach, Marco Thomas

2020Journal of Virology22 citationsDOIOpen Access PDF

Abstract

HCMV is a major global health concern, and antiviral chemotherapy remains problematic due to toxicity of available compounds and the emergence of drug-resistant viruses. Thus, an HCMV vaccine represents a priority for both governmental and pharmaceutical research programs. A major obstacle for the development of a vaccine is a lack of knowledge of the nature and specificities of protective immune responses that should be induced by such a vaccine. Glycoprotein B of HCMV is an important target for neutralizing antibodies and, hence, is often included as a component of intervention strategies. By generation of fusion-active gB chimeras, we were able to identify target structures of neutralizing antibodies that potently block gB-induced membrane fusion. This experimental system provides an approach to screen for antibodies that interfere with gB's fusogenic activity. In summary, our data will likely contribute to both rational vaccine design and the development of antibody-based therapies against HCMV.

Topics & Concepts

EctodomainBiologyVirologyAntibodyLipid bilayer fusionHuman cytomegalovirusGlycoproteinAntigenImmunologyVirusMolecular biologyReceptorGeneticsCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsToxoplasma gondii Research Studies